Combination therapy for effecting weight loss and treating obesity
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
1. A method for effecting a weight loss in a subject in need thereof comprising administering to said subject continually over a significant period of time an 8 mg daily dose of phentermine and in combination therewith a daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone.
2. The method of claim 1 wherein the significant period of time is from 4 weeks to 67 weeks.
3. The method of claim 1 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 50 mg.
4. The method of claim 3 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is from about 50 mg to about 400 mg.
5. The method of claim 1 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 100 mg.
6. The method of claim 1 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 200 mg.
7. A method for effecting weight loss in a subject in need thereof comprising administering to said subject continuously over a significant period of time a 10 mg daily dose of phentermine and in combination therewith a daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone.
8. The method of claim 7 wherein the significant period of time is from 4 weeks to 67 weeks.
9. The method of claim 7 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phenetermine alone is at least about 50 mg.
10. The method of claim 9 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is from about 50 mg to about 400 mg.
11. The method of claim 7 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 100 mg.
12. The method of claim 7 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 200 mg.
13. A method for effecting weight loss in a subject in need thereof comprising administering to said subject continuously over a significant period of time a 15 mg daily dose of phentermine and in combination therewith a daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone.
14. The method of claim 13 wherein the significant period of time is from 4 weeks to 67 weeks.
15. The method of claim 13 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 50 mg.
16. The method of claim 15 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is from about 50 mg to about 400 mg.
17. The method of claim 13 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 100 mg.
18. The method of claim 13 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 200 mg.
19. A method for effecting weight loss in a subject in need thereof comprising administering to said subject continuously over a significant period of time a 20 mg daily dose of phentermine and in combination therewith a daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone.
20. The method of claim 19 wherein the significant period of time is from 4 weeks to 67 weeks.
21. The method of claim 19 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 50 mg.
22. The method of claim 21 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is from about 50 mg to about 400 mg.
23. The method of claim 19 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 100 mg.
24. The method of claim 19 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 200 mg.